The Effect of HIF-1α on Invasion and Metastasis of Gallbladder Cancer by Regulating the Epithelial-Mesenchymal Transformation
-
摘要:
目的 探讨HIF-1α对胆囊癌细胞迁移侵袭的影响及其相关调控机制。 方法 构建GBC-SD细胞,使用慢病毒转染,分别得到实验组(HIF-1α shRNA)、阴性对照组(空载慢病毒转染)和空白对照组(未处理)。蛋白质免疫印迹法检测E-Cadherin、N-Cadherin蛋白的表达水平,GBC-SD细胞的迁移能力用细胞划痕实验检测,GBC-SD细胞的侵袭能力用Transwell 侵袭实验检测。 结果 与对照组相比,实验组E-Cadherin蛋白的表达水平明显升高(P < 0.001),N-Cadherin蛋白的表达水平明显降低(P < 0.001),对照组之间E-Cadherin、N-Cadherin蛋白的表达水平无明显差异(P > 0.05)。实验组细胞划痕愈合度较对照组低(P < 0.001)、穿模个数较对照组少(P < 0.001),而对照组之间细胞划痕愈合度、穿模个数无明显差异(P > 0.05)。 结论 靶向敲低HIF-1α可以降低GBC-SD细胞的迁移侵袭能力,其作用机制可能与调控上皮-间充质转化有关。 Abstract:Objective To explore the effect of HIF-1α on the migration and invasion of gallbladder cancer cells and its related regulatory mechanism. Methods GBC-SD cells were constructed and transfected with lentivirus, and the experimental group (HIF-1α shRNA), negative control group (empty lentivirus transfection) and blank control group (untreated) were obtained respectively. The expression levels of E-Cadherin, and N-Cadherin proteins were detected by Western blotting assay, Cell scratch assay was ued to detect the migratory ability of GBC-SD cells, and Transwell invasion assay was uesd to detect the invasive ability of GBC-SD cells. Results Compared with the control group, the expression level of E-Cadherin protein in the experimental group was significantly increased (P < 0.001), while the expression level of N-Cadherin protein was significantly decreased (P < 0.001), and there was no remarkable difference in the expression level of E-Cadherin and N-Cadherin proteins between the control groups (P both>0.05). In the experimental group, the cell scratch healing degree was inferior to the control group (P < 0.001) , and the number of penetrating molds was also inferior to the control group (P < 0.001), while there was no obvious otherness in the cell scratch healing degree and the number of penetrating molds between the control groups (P > 0.05). Conclusion Targeted knockdown of HIF-1α can reduce the migration and invasion ability of gallbladder cancer cells, and its mechanism of action may be related to the regulation of epithelial mesenchymal transition. -
表 1 抗体信息
Table 1. Antibody information
抗体名称 厂家 货号 稀释浓度 种属 GAPDH PROTEINTECH 10068-1-AP 1∶5000 Mouse HIF1α Affinity Biosciences AF1009 1∶5000 Rabbit E-Cadherin Affinity Biosciences AF0131 1∶5000 Rabbit N-cadherin Affinity Biosciences AF5239 1∶5000 Rabbit Anti-Rabbit IgG (H+L) Antibody,Peroxidase-Labeled KPL 074-1506 1∶5000 Anti-Mouse IgA + IgG + IgM (H+L) Antibody,Human Serum Adsorbed and Peroxidase-Labeled KPL 074-1807 1∶5000 表 2 各组细胞愈合度和穿模细胞数($ \bar x \pm s$)
Table 2. Cell healing degree and number of perforated cells in each group ($ \bar x \pm s $)
组别 48 h划痕愈合度(%) 穿模细胞数(个) Control组 69.96$ \pm $0.47 215.00$ \pm $2.94 sh-NC组 69.25$ \pm $0.86 215.33$ \pm $2.05 sh-HIF1α组 44.51$ \pm $0.93ab 121.67$ \pm $1.69ab χ2/F 18.00 1108.18 P <0.001* <0.001* 与sh-NC组比较,aP < 0.001;与Control组比较,bP < 0.001;*P < 0.05。 -
[1] China Anti-cancer Association. 中国恶性肿瘤整合诊治指南: 胆囊癌[J]. 肿瘤,2022,42(3):188-202. [2] Narayan R R,Creasy J M,Goldman D A,et al. Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations[J]. Cancer,2019,125(4):575-585. doi: 10.1002/cncr.31850 [3] Siegel R L,Miller K D,Wagle N S,et al. Cancer statistics,2023[J]. CA Cancer J Clin,2023,73(1):17-48. doi: 10.3322/caac.21763 [4] Sahara K,Tsilimigras D I,Kikuchi Y,et al. Defining and predicting early recurrence after resection for gallbladder cancer[J]. Ann Surg Oncol,2021,28(1):417-425. doi: 10.1245/s10434-020-09108-y [5] de Savornin L E,de Bitter T,Verhoeven R,et al. Trends in treatment and survival of gallbladder cancer in the netherlands; Identifying gaps and opportunities from a nation-wide cohort[J]. Cancers (Basel),2020,12(4):918 doi: 10.3390/cancers12040918 [6] McKeown S R. Defining normoxia,physoxia and hypoxia in tumours-implications for treatment response[J]. Br J Radiol,2014,87(1035):20130676. doi: 10.1259/bjr.20130676 [7] Vaupel P,Harrison L. Tumor hypoxia: Causative factors,compensatory mechanisms,and cellular response[J]. Oncologist,2004,9(Suppl 5):4-9. [8] Muthamil S,Kim H Y,Jang H J,et al. Understanding the relationship between cancer associated cachexia and hypoxia-inducible factor-1[J]. Biomed Pharmacother,2023,163(7):114802. [9] Wang G L,Semenza G L. Molecular basis of hypoxia-induced erythropoietin expression[J]. Curr Opin Hematol,1996,3(2):156-162. doi: 10.1097/00062752-199603020-00009 [10] Prabhakar N R,Semenza G L. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2[J]. Physiol Rev,2012,92(3):967-1003. doi: 10.1152/physrev.00030.2011 [11] Jiang B H,Rue E,Wang G L,et al. Dimerization,DNA binding,and transactivation properties of hypoxia-inducible factor 1[J]. J Biol Chem,1996,271(30):17771-17778. doi: 10.1074/jbc.271.30.17771 [12] Jiang B H,Zheng J Z,Leung S W,et al. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension[J]. J Biol Chem,1997,272(31):19253-19260. doi: 10.1074/jbc.272.31.19253 [13] Wang G L,Jiang B H,Rue E A,et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension[J]. Proc Natl Acad Sci U S A,1995,92(12):5510-5514. doi: 10.1073/pnas.92.12.5510 [14] Maxwell P H,Wiesener M S,Chang G W,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis[J]. Nature,1999,399(6733):271-275. doi: 10.1038/20459 [15] Song H,Qiu Z,Wang Y,et al. HIF-1alpha/YAP signaling rewrites glucose/Iodine metabolism program to promote papillary thyroid cancer progression[J]. Int J Biol Sci,2023,19(1):225-241. doi: 10.7150/ijbs.75459 [16] He F,Xiao H,Cai Y,et al. ATF5 and HIF1alpha cooperatively activate HIF1 signaling pathway in esophageal cancer[J]. Cell Commun Signal,2021,19(1):53. doi: 10.1186/s12964-021-00734-x [17] Batmunkh E,Shimada M,Morine Y,et al. Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma[J]. Int J Clin Oncol,2010,15(1):59-64. doi: 10.1007/s10147-009-0011-7